StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Rating) in a research note published on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Price Performance NASDAQ:GLMD opened at $3.60 on Friday. Galmed Pharmaceuticals has a 12-month low of $3.43 and a 12-month high of $14.18. […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom , ,Cambridge Investment Research Advisors Inc ,Institutional Trading Of Galmed Pharmaceuticals ,Galmed Pharmaceuticals ,News Ratings For Galmed Pharmaceuticals Daily ,Raymond James Financial Services Advisors Inc ,Galmed Pharmaceuticals Price Performance ,Galmed Pharmaceuticals Ltd ,Nasdaq ,Millennium Management ,Get Rating ,James Financial Services Advisors ,Cambridge Investment Research Advisors ,Pharmaceuticals Ltd ,Galmed Pharmaceuticals Daily ,